"Analyzing President Trump's Executive Order on Prescription Drug Prices in the U.S."
Read "Analyzing President Trump's Executive Order on Prescription Drug Prices in the U.S." on WALY Radio
"Analyzing President Trump's Executive Order on Prescription Drug Prices in the U.S."
[!CDATA[President Donald Trump recently signed an executive order aimed at reducing prescription drug prices in the U.S. by pressuring drugmakers to lower their prices voluntarily within 30 days or face potential limits on what the government will pay. The order also tasks Health and Human Services Secretary Robert F. Kennedy Jr. with developing a new rule that ties drug prices in the U.S. to lower prices paid by other countries if favorable deals are not reached. Trump claimed that the U.S. was subsidizing other countries' healthcare by paying significantly higher prices for the same drugs. However, experts point out that the higher drug prices in the U.S. are largely due to the way drug prices are negotiated in the country compared to other developed nations. A report by the RAND research organization found that drug prices in the U.S. were 2.78 times higher than in 33 comparable countries, with brand-name drugs showing the largest price gap. In the U.S., drug companies can price medications higher due to the fragmented nature of the drug market, where they negotiate with individual insurers or pharmacy benefit managers. In contrast, many other countries have a single regulatory agency that negotiates prices on behalf of the entire population, giving them more bargaining power. Trump's executive order introduces a "most favored nation" pricing model to align U.S. drug prices with those in comparable developed countries if drugmakers do not voluntarily lower costs. While the order may impact drug prices for Medicare and Medicaid beneficiaries, its effect on Americans with private health insurance remains uncertain. Other countries may not necessarily pay more if the U.S. pays less for prescription drugs, as they could negotiate increased discounts or enter into secret arrangements to maintain lower prices. The pharmaceutical industry's profit-driven motives, including the use of patents to prevent cheaper alternatives, contribute to the high drug prices in the U.S. In conclusion, Trump's executive order aims to address the issue of high prescription drug prices in the U.S. by potentially linking them to lower prices paid by other countries. However, the complex dynamics of the global pharmaceutical market and profit-driven practices within the industry pose challenges to achieving significant cost reductions for consumers.]]